QuidelOrtho reported FY 2025 total revenues of USD 2.73 billion (-2%), including Labs revenue of USD 1.51 billion (+6%), Immunohematology revenue of USD 543.8 million (+4%), Donor Screening revenue of USD 52.6 million (-54%) and Point of Care revenue of USD 601.6 million (-13%). Respiratory products represented about 15% of FY 2025 total revenues, with COVID-19-related revenue of USD 80.2 million. Cost of sales (excluding amortization) was USD 1.46 billion (53.3% of total revenues). Selling, marketing and administrative expense was USD 746.3 million, R&D expense was USD 186.2 million, and amortization of intangible assets was USD 189.2 million. QuidelOrtho recorded restructuring, integration and other charges of USD 263.6 million and a non-cash goodwill impairment charge of USD 700.7 million; interest expense, net was USD 177.6 million. The company posted a net loss of USD 1.13 billion, with loss before taxes of USD 1.11 billion and income tax expense of USD 24.1 million. For FY 2025, net cash provided by operating activities was USD 105.2 million and capital expenditures were approximately USD 182 million. Cash and cash equivalents were USD 169.8 million at December 28, 2025, with USD 596.6 million available under the Revolving Credit Facility. Business updates included a wind-down of the U.S. donor screening portfolio (VIP platform and microplate assays), expected to be substantially complete by H1 2026; the launch in Q2 2025 of a multi-year Optimization Plan targeting approximately USD 100 million of cumulative pre-tax charges through 2027 and approximately USD 50 million of net cost savings through 2027; and a strategic refocusing of Molecular Diagnostics, including plans to discontinue development of the SAVANNA platform (exit expected to be substantially complete by H1 2027) and an intent to acquire LEX Diagnostics. QuidelOrtho also cited incremental costs from U.S. tariffs implemented in April 2025, which it said it has thus far substantially offset through operating measures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quidelortho Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001906324-26-000008), on February 19, 2026, and is solely responsible for the information contained therein.